Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Pharmaceutical Co. Ltd.

Division of Roche
www.chugai-pharm.co.jp

Latest From Chugai Pharmaceutical Co. Ltd.

Some Caution Over 'People’s Hope' Remdesivir As China Trials Progress

Although Gilead’s remdesivir shows promise against the coronavirus, efficacy is not guaranteed, one antiviral company executive tells Scrip, as multiple other potential therapies and vaccines move forward.

Coronavirus COVID-19 Clinical Trials

China Taps Roche Antibody, Green Lights Testing Kits For Coronavirus Arsenal

Kicking a rapid response mechanism into full gear, China approves Roche’s Actemra as a new treatment for coronavirus along with a flurry of testing kits.

China Infectious Diseases

Alexion Win Thwarts Roche’s EU Fast-Track Hopes

Roche hopes that its investigational drug satralizumab for neuromyelitis optica spectrum disorder will win EU approval in the second half of 2020.

EU Accelerated Assessment Tracker

EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.

Europe Drug Review
See All

Company Information

UsernamePublicRestriction

Register